Molecular and Cellular Biology, November 1998, p. 6666-6678, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Cancer Biology Program and Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215
Received 23 March 1998/Returned for modification 28 April 1998/Accepted 21 July 1998
| |
ABSTRACT |
|---|
|
|
|---|
Epithelial cell differentiation is regulated by specific
combinations of growth factors, hormones, and extracellular matrix (ECM). How these divergent signals are integrated is largely unknown. We used primary cultures of normal human bronchial epithelial cells
(NHBEs) to investigate mechanisms of signal integration. In defined,
serum-free media, NHBEs undergo mucosecretory differentiation only when
grown in the presence of retinoids and on the appropriate substratum
(collagen gels). We identified the retinoic acid receptor
(RAR
)
gene as an early marker of NHBE differentiation. In contrast to
immortalized cell lines, in NHBEs strong retinoid-induced RAR
transcription occurs only when cells are grown on collagen gels, and it
requires new protein synthesis and a cis-acting element that maps outside the known RAR
promoter elements. NHBEs grown on
collagen gels exhibit reduced epidermal growth factor (EGF)-induced Raf, MEK, and mitogen-activated protein kinase (MAPK) activity. This
correlates with a specific inability to achieve high levels of
p66SHC tyrosyl phosphorylation and association of
p66SHC with GRB2, despite high levels of EGF receptor
(EGFR) autophosphorylation. Notably, inhibition of EGFR or MEK/MAPK
activation replaces the ECM requirement for RAR
induction. Our
results strongly suggest that a key mechanism by which specific ECMs
facilitate retinoid-induced mucosecretory differentiation of NHBEs is
by restricting the level of EGFR-dependent MEK/MAPK activation evoked
by autocrine and/or paracrine EGFR ligands.
| |
INTRODUCTION |
|---|
|
|
|---|
Epithelial cell differentiation is a complex process that results from the integration of growth factor-, hormone-, and extracellular matrix (ECM)-derived signals (for reviews see references 17 and 38). The respiratory epithelium provides a good model system for the study of signal integration, since normal bronchial epithelial cell differentiation requires the correct combination of growth factors, retinoids, and ECM (73, 74). In vivo, the upper airways are populated with basal, ciliated, and mucosecretory (goblet) cells (reviewed in reference 24), which rest on a thin basement membrane and a thick lamina propria rich in ECM molecules such as collagens, laminin, fibronectin, and heparan sulfate proteoglycans. Vitamin A (retinol)-deficient animals develop lesions along their upper airways in which mucociliary cells are replaced with highly keratinized squamous epithelia (44, 72), indicating a critical role for retinoids in normal respiratory cell differentiation. When grown ex vivo on plastic dishes in defined serum-free media without retinoids, cultures of normal tracheal/bronchial epithelial cells undergo squamous metaplasia upon reaching confluence (30, 54). Although retinoid treatment inhibits expression of the squamous phenotype under these culture conditions (28, 30, 54), it does not stimulate mucociliary differentiation. For mucosecretory cell differentiation ex vivo, tracheal/bronchial epithelial cells must be cultured on type I collagen gels in the presence of retinoids (29, 55, 73) but with limited amounts of growth factors, since high doses of epidermal growth factor (EGF), for example, are inhibitory (23, 74).
Growth factors signal by binding to and increasing the catalytic
activity of receptor tyrosine kinases (RTKs) (for a review, see
reference 34). Autophosphorylation of the RTK on its
cytoplasmic tail results in the recruitment of several secondary
signaling molecules. These usually include the SHC-GRB2-SOS and/or
GRB2-SOS complexes, which participate in Ras activation,
phosphatidylinositol 3' kinase, SHP-2, and phospholipase C-
.
Ultimately, several downstream events occur, including activation of
the mitogen-activated protein kinases (MAPKs) Erk1 and Erk2.
ECM transmits signals via various cell adhesion molecules (for a review, see reference 57). Integrins are the most widely studied of this group of molecules (for a review, see reference 10). Much is known about the signaling events that are evoked immediately upon integrin ligation and attachment of cells to ECM. Typically, acute engagement of integrins leads to the activation of protein tyrosine kinases (PTKs) such as FAK and Src family PTKs, the subsequent recruitment of many of the same signaling molecules that are recruited to RTKs, and the activation of downstream pathways such as phosphatidylinositol 3' kinase (35) and MAPK (9, 59). In contrast, little is known about the specific effects of long-term cell-ECM interactions on signaling pathways.
Retinoids signal by binding to two classes of receptors, retinoic acid
receptors (RARs) and retinoid X receptors (RXRs), which belong to the nuclear hormone receptor superfamily of transcription factors (for a review, see reference 8). At least
three genes encode each type of receptor (denoted
,
,
), and
typical responses are transduced through binding of RAR-RXR
heterodimers to retinoic acid response elements (RAREs) in the
promoters of target genes.
Although much is known about how growth factors, retinoids, and ECM signal in isolation, virtually nothing is understood about how these disparate signals are integrated to direct complex responses such as differentiation and/or how signal integration is perturbed under pathological conditions such as cancer. We investigated the molecular basis for signal integration during mucosecretory differentiation of normal human bronchial epithelial cells (NHBEs). We found striking differences in the established paradigms for growth factor, retinoid, and ECM signaling pathways, which largely have been elucidated in studies using immortalized and/or transformed cell lines. These studies stress the importance of using normal primary cell systems to study general epithelial signal transduction pathways and provide new insight into how divergent pathways may cooperate to regulate normal physiologic responses such as differentiation in vivo.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture and immunofluorescence staining. NHBEs were obtained from Clonetics Corp. and were grown as recommended by the manufacturer. Collagen gels were prepared by using Vitrogen 100 (Collagen Corp.) as described elsewhere (73). Fifteen to 24 h prior to experiments, cells were seeded at 15,000 to 25,000 cells/cm2 in retinoid- or growth factor-deficient BEGM (Clonetics). Where indicated, NHBEs were cultured with the anti-EGF receptor (EGFR) neutralizing antibody LA1 (Upstate Biotechnology Inc. [UBI]) or control immunoglobulin G (IgG) (rabbit anti-mouse IgG; product no. 315-005-003; Jackson Laboratories). When necessary, NHBEs were released from collagen gels by treatment with collagenase (type IA; Sigma) or from plastic dishes by trypsin (Clonetics). Cells were collected by centrifugation and either cytospun onto glass slides, frozen in liquid nitrogen, or used immediately for nuclear extract preparation. For immunofluorescence staining, cytospun cells were fixed in methanol and incubated with the antimucin monoclonal antibody (MAb) 17B1 (a gift from R. Wu; 1:1,000) before detection with rhodamine-conjugated goat anti-mouse IgG (Tago).
Plasmid constructions.
The enhancer trap retroviral vector
pLEN
was constructed from pLNSX (a gift from D. Miller)
by deleting nucleotides 3217 to 3621, which removes the entire U3
region except for 8 bp downstream of the inverted repeat and 21 bp
upstream of the repeat region. The luciferase cDNA was amplified by PCR
from pXP2 (a gift from S. Nordeen) and subcloned into
pLEN
to generate pLEN
LUC. A fusion of the
luciferase cDNA to the 5-kbp 5' flanking region of the human RAR
promoter was amplified by PCR from pX5 (48) and subcloned
into pLEN
to generate pLEN
5LUC. Further
details regarding plasmid constructions are available upon request.
Immunoblotting.
Cell lysis and immunoblotting were performed
as described elsewhere (40) except that Nonidet P-40 buffer
contained 20 mM NaF and 20 mM
-glycerophosphate with no
ZnCl2. Primary antibodies included
RAR
(antibody
directed against RAR
) (537N [66]), 1 µg/ml;
MAPK (Erk1/2) (C1; a gift from J. Blenis), 1:5,000;
phospho-MAPK
(New England Biolabs), 1:1,000;
PTP-1B (UBI), 1:1,000;
SHP2
(Transduction Laboratories), 1:1,000;
MEK1 (724; a gift from R. L. Erikson), 1:1,000; antiphosphotyrosine antibody 4G10 (UBI), 1:7,000;
EGFR (sc-03; Santa Cruz), 1:100;
Raf (sc-133; Santa Cruz), 1:100;
SHC (Transduction Laboratories), 1:500; and
GRB2 (sc-255; Santa
Cruz), 1:100.
RNase protection assays and RT-PCR.
RNA was isolated by
using TRIzol Reagent (GibcoBRL). RNA probes were generated by in vitro
transcription (Promega Corp.) from cDNAs for human PTP-1B
(63),
-actin (a gift from T. Maniatis), and RAR
(nucleotides 1280 to 1677) in the presence of
[
-32P]UTP (800 Ci/mmol; NEN). RNase protection assays
were performed as described previously (3). Each probe
(5 × 105 to 10 × 105 cpm) was
incubated with 5 µg of total cellular RNA or yeast RNA for 12 to
18 h at 45°C. Following hybridization, reaction products were
digested with RNase A (40 µg/ml; Sigma) and RNase T1 (2 µg/ml; Sigma) for 30 min at 30°C. For reverse transcription-PCR
(RT-PCR), total cellular RNA (860 ng) was reverse transcribed with
Moloney murine leukemia virus reverse transcriptase (GibcoBRL). cDNAs were amplified by PCR with primer set
5'-GACCTGGAGGAGCCCGAAAAAGTG-3' plus
5'-GGGAGATGGTCAGTCTGCTGCC-3' (401 bp; for RAR
) or
5'-GCTGCACGTCCACCGGAACAGC-3' plus
5'-CAGGCAGGGTGGCCAGAACGGG-3' (450 bp; for RXR
) in
reaction mixtures containing 10 µM deoxynucleoside triphosphates and
5 µCi of [
-32P]dCTP (6,000 Ci/mmol; NEN).
EMSAs.
Nuclear extracts were prepared as described
previously (61) except that buffer C was supplemented with
20 mM NaF, 20 mM
-glycerophosphate, 1 mM sodium orthovanadate,
leupeptin (10 µg/ml), antipain (1 µg/ml), pepstatin A (1 µg/ml),
and aprotinin (1 µg/ml). The
RARE electrophoretic mobility shift
assay (EMSA) probe (14), which spans
59 to
33 of the
human RAR
promoter, was labeled with [
-32P]dCTP
(6,000 Ci/mmol; NEN), and 10 to 20 fmol was used in binding reaction
mixtures containing 20 mM HEPES (pH 8.0), 53 mM NaCl, 2.6 mM
MgCl2, 0.13 mM EDTA, 0.5 mM dithiothreitol (DTT), 11.3% glycerol, 0.2 mg of salmon testes DNA (Sigma) per ml, and 5 to 10 µg
of nuclear extract. Competitor DNAs included either the unlabeled
RARE or mRARE. The mRARE construct
(5'-TCGAGGGTAGGGTCTGCAGAAATCGCACTCG-3' and
5'-TCGACGAGTGCGATTTCTGCAGACCCTACCC-3')
contains seven point mutations (underlined) in the
RARE which
disrupt RAR-RXR binding (70). Nuclear extracts were
preincubated either in the presence or in the absence of a 100-fold
molar excess of competitor DNA or 2 µl of antibodies against RAR
1
(sc-551; Santa Cruz), RAR
(sc-773; Santa Cruz), RAR
(537N), or
RXR
and RXR
(gifts from W. Chin) for 10 min at room temperature,
followed by the addition of probe and further incubation for 20 min at
room temperature. DNA-bound complexes were resolved on 4% 0.5×
Tris-borate-EDTA gels.
Transfections, retroviral infections, and reporter gene assays. NHBEs were transiently transfected by using Lipofectamine (GibcoBRL). Two micrograms of pRARE3tkluc (14) and 500 ng of pEFCAT (47), or 2.5 µg of pUC19 alone, were incubated with 12 µl (24 µg) of Lipofectamine in 800 µl of BEGM for 30 min at room temperature. BEGM (3.2 ml) was subsequently added to the DNA-lipid complexes, and the complete mixture was applied to cells on 100-mm-diameter plastic dishes for 2 h at 37°C. Retroviruses were generated by using the BING amphotropic packaging cell line (a gift from W. Pear) as described previously (51). Infections were carried out in the presence of Polybrene (4 µg/ml) at 37°C for 4 h. Following transfection or infection, cells were subcultured onto plastic or collagen gels and treated with 10 nM Ro 19-0645 15 h later. Twenty-four hours following retinoid treatment, cells were harvested, resuspended in 100 mM Tris-HCl (pH 7.5), and subjected to freeze-thaw lysis, and cellular debris was removed by ultracentrifugation. Luciferase and chloramphenicol acetyltransferase (CAT) activities were measured as described previously (48) except that the luciferase reaction buffer was supplemented with 0.6 mM coenzyme A.
Growth factor stimulations, immunoprecipitations, and kinase
assays.
Cells were starved for 20 h in BEGM containing 10 nM
Ro 19-0645 but lacking EGF and insulin. Some cultures were treated with 10 µM PD 098059 prior to the addition of EGF (0.1 nM) and/or insulin (5 µg/ml) (Clonetics). Cells were lysed on their respective substrata in Nonidet P-40 buffer, and debris was removed by ultracentrifugation (100,000 × g, 20 min). Immunoprecipitations were
performed with 2 µl of anti-MEK1 MAb 3D9 (Zymed)/150 µg of lysate,
3 µl of
Erk2 (sc-154; Santa Cruz)/150 µg of lysate, 4 µl of
Raf (sc-133; Santa Cruz)/300 µg of lysate, 2 µl of
SHC
(Transduction Laboratories)/200 µg of lysate, 2 µl of
GRB2
(sc-255; Santa Cruz)/200 µg of lysate, or 2 µl of
EGFR (sc-120;
Santa Cruz)/200 µg of lysate. Immunoprecipitates were washed in lysis
buffer containing 2 mM sodium orthovanadate, 20 mM NaF, and 20 mM
-glycerophosphate. For Erk2 activity assays, immune complexes were
washed additionally in kinase buffer (20 mM HEPES [pH 7.4], 10 mM
MgCl2, 1 mM DTT, 1 mM EGTA) and resuspended in 30 µl of
kinase buffer containing 50 µM ATP, 5 µCi of
[
-32P]ATP (6,000 Ci/mmol; NEN), and 10 µg of myelin
basic protein. For MEK activity assays, immune complexes were washed
additionally in kinase buffer (50 mM Tris [pH 8.0], 10 mM
MgCl2) and resuspended in 30 µl of kinase buffer
containing 50 µM ATP, 5 µCi of [
-32P]ATP (6,000 Ci/mmol; NEN), and 2 µg of glutathione S-transferase (GST)-ERK1(K63M). For Raf activity assays, immune complexes were washed additionally in kinase buffer (25 mM HEPES [pH 7.4], 10 mM
MgCl2, 2 mM MnCl2, 1 mM DTT) and resuspended in
50 µl of kinase buffer containing 25 µM ATP, 20 µCi of
[
-32P]ATP (6,000 Ci/mmol; NEN), and 1 µg of
GST-MEK(K97A). MEK and Erk2 reactions were carried out at 30°C for 20 and 15 min, respectively, before being terminated by the addition of
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer. Raf activity assays were performed at room temperature
for 30 min. Terminated kinase reaction products were resolved by
SDS-PAGE and either dried or transferred to Immobilon-P (Millipore) for
PhosphorImager (Molecular Dynamics) analysis and immunoblotting.
| |
RESULTS |
|---|
|
|
|---|
Previous work established that mucosecretory differentiation is
induced when NHBEs are grown on type I collagen gels in defined, serum-free media in the presence of all-trans-retinoic acid
(T-RA) (73). Differentiation, as assessed by mucous
glycoprotein expression, is inefficient under these conditions (Fig.
1a), possibly due to the rapid rate of
T-RA metabolism in such epithelial cells. Unfortunately, however, high
doses of T-RA are toxic to NHBEs (data not shown). We searched for
alternative, synthetic retinoids that might induce
differentiation in a large percentage of NHBEs at relatively low doses.
Compared to T-RA, the synthetic retinoid Ro 19-0645 (2) markedly enhanced differentiation (Fig. 1b). Importantly, Ro 19-0645-treated NHBEs retained the ECM requirement for
mucosecretory differentiation (Fig. 1c to f). Based on these findings,
as well as its ability to bind nuclear hormone receptors (2)
and stimulate transcription from the RAR
RARE (
RARE) (Fig. 3d),
we concluded that Ro 19-0645 is a useful tool for dissecting retinoid signaling in this primary cell system.
|
Although MAb 17B1 (39) recognizes an airway-specific mucin,
the gene encoding this protein has not been cloned, and no other clearly defined markers for NHBE mucosecretory differentiation exist.
We sought to identify additional markers that would facilitate our
molecular analysis of signal integration. We suspected that RAR
might be such a marker. In mice, RAR
is highly expressed in the
developing respiratory epithelium, and its expression coincides with
the onset of cytodifferentiation (15). Loss of RAR
expression has been reported for a number of epithelial cell-derived
malignancies (21, 22, 27, 49, 62, 65); notably, it is one of
the most frequent events observed in lung cancer (21, 49),
in which NHBE differentiation is aberrant. Moreover, defective RAR
expression is an early event in epithelial carcinogenesis
(42). RAR
is the prototypical retinoid-inducible
gene in cell lines (13, 14, 43): its transcription is
induced in an immediate-early fashion upon retinoid treatment,
peaking by 6 h and independent of new protein synthesis (13,
43). We observed that RAR
also was induced by
retinoids in primary NHBEs. Interestingly, however, unlike in
cell lines, retinoid only induced substantial RAR
mRNA (Fig.
2a and b) and protein (Fig. 2c)
expression when NHBEs were grown on collagen gels, the appropriate ECM
for mucosecretory differentiation. Moreover, unlike in cell lines,
RAR
mRNA induction in NHBEs was delayed and required new protein
synthesis (Fig. 2b). RAR
mRNA stability was unaffected by ECM (Fig.
2d), implying that growth on collagen gels is required for high levels
of retinoid-dependent transcription. Since peak RAR
RNA
and protein expression (Fig. 2b and c) occurred well before the peak
of mucous glycoprotein expression (5 to 10 days [Fig. 2e]), and
only under conditions that allow NHBE differentiation, we used RAR
as an early marker for mucosecretory differentiation.
|
ECM-derived signaling pathways could regulate the activity of the
RARE either through direct regulation of retinoid receptors or indirectly through heterologous elements in the RAR
promoter. Nuclear extracts prepared from NHBEs growing on either collagen gels or plastic demonstrated
RARE binding activity in vitro, although binding activity was reduced in cells growing on plastic. In
both cases, a single specific shifted species was observed (Fig. 3a). Complex
formation was inhibited by preincubation of nuclear extracts with
RAR
antiserum and supershifted by preincubation with RXR
and RXR
antisera (Fig. 3b), suggesting that these receptors are in the complex. Moreover, the EMSA complex migrated in a manner similar to that of a complex generated with in vitro-translated RARs
and RXRs, suggesting that retinoid receptors were the sole components of the EMSA complex (data not shown). RT-PCR analysis confirmed the expression of both RAR
and RXR
mRNAs in cells growing on plastic (Fig. 3c). These data indicate that NHBEs growing on
plastic express RARs and RXRs that are capable of forming appropriate heterodimeric complexes on the
RARE in vitro, but they suggest that the efficiency of complex formation may be reduced.
|
To determine whether this difference in the level of
RARE binding
activity contributes to reduced RAR
transcription, we transiently
transfected a
RARE/heterologous tk promoter-luciferase construct into NHBEs. Notably, cells growing on plastic actually supported higher levels of retinoid-dependent transcription
from this promoter than cells growing on collagen (Fig. 3d,
left). Importantly, the transfection conditions did not interfere
with the synergistic induction of endogenous RAR
by collagen gels and retinoid (Fig. 3d, right). Thus, the reduced
RARE
binding activity observed in nuclear extracts from cells growing on
plastic is still sufficient to confer high levels of
retinoid-dependent transcription to minimal
RARE-containing
promoters in NHBEs. Moreover, these data suggest that elements mapping
outside the
RARE are required to observe ECM-dependent effects on
RAR
transcription. Conceivably, stable integration of reporter
constructs may be necessary for observation of proper transcriptional
regulation of larger fragments of the RAR
promoter. Since the
limited life span of primary NHBE cultures does not allow selection of
stably transfected clones, we introduced reporter constructs into NHBEs by using enhancer trap retroviruses (see Materials and Methods). Following infection of NHBEs on plastic with retroviruses
carrying luciferase alone (LEN
LUC) or a fusion of 5 kbp
of the RAR
5' flanking region to luciferase (LEN
5LUC), cells were subcultured onto either
plastic or collagen gels. Retinoid treatment of
LEN
5LUC-infected cells, but not
LEN
LUC-infected cells, resulted in a threefold increase
in luciferase activity regardless of the substratum (Fig. 3e, left).
Under the same conditions, control mock-infected cells demonstrated
strong synergy between ECM and retinoid for induction of
endogenous RAR
expression (Fig. 3e, right). These data strongly
suggest that sequences outside the 5 kbp 5' flanking region of the
RAR
gene are required to reproduce correct transcriptional
regulation by collagen gels and retinoid. Consistent with our
results, a 3.8-kbp fragment of the 5' flanking region of the murine
RAR
gene previously was found to be unable to direct
-galactosidase expression to the bronchi of transgenic mice
(45).
Since the effects of ECM on RAR
expression did not map exclusively
to the
RARE, we suspected that collagen gels might instead modulate
a heterologous signaling pathway that indirectly communicated with RARs
and RXRs on the endogenous RAR
gene. NHBE cell growth is regulated
by a number of autocrine and paracrine factors besides retinoids. Some of these factors include agonists for RTKs,
such as EGF, insulin, platelet-derived growth factor (PDGF), and
hepatocyte growth factor (68, 74, 75). We therefore asked
whether RTK signaling might be modulated by differentiation-promoting
collagen gels. We examined the ability of a combination of EGF and
insulin, the only two exogenously supplied RTK agonists in the NHBE
culture medium, to evoke downstream signaling events. NHBEs were grown in the presence of retinoid for 2 days, starved for exogenous EGF and insulin during the last 20 h, and then subjected to acute stimulation with both growth factors. Antiphosphotyrosine
immunoblotting of whole-cell lysates indicated a number of differences
in basal and growth factor-induced protein tyrosyl phosphorylation that were substratum dependent. In starved cells, a 120-kDa protein was
hypophosphorylated and a 130-kDa protein was hyperphosphorylated on
collagen gels (Fig. 4a, closed arrows).
When grown on plastic, growth factors induced the tyrosyl
phosphorylation of four major proteins, with molecular masses of 180, 68, 52, and 43 kDa (Fig. 4a). Strikingly, however, growth factors
selectively failed to promote extensive tyrosyl phosphorylation of the
68- and 43-kDa proteins (Fig. 4a, open arrows) in cells growing on
collagen gels. Thus, growth on collagen gels diminishes specific
aspects of RTK signaling in NHBEs.
|
In most other systems, the MAPKs Erk1 and Erk2 are the major 42- to 44-kDa tyrosyl phosphoproteins upon growth factor stimulation (reviewed in reference 52), which led us to believe that the 43-kDa species that was hypophosphorylated on collagen gels might be a MAPK. To directly test this hypothesis, we analyzed growth factor-stimulated Erk1 and Erk2 activation by immunoblotting. As evidenced by the characteristic reduction of electrophoretic mobility of their activated forms, we observed less growth factor-induced Erk1 and Erk2 activation over time in NHBEs cultured on collagen gels than in those cultured on plastic dishes (Fig. 4b). Immune complex Erk2 kinase assays supported the immunoblotting data and directly demonstrated that following growth factor stimulation, Erk2 had a lower specific activity in cells growing on collagen gels than in cells growing on plastic dishes (Fig. 4c). Immune complex kinase assays revealed that the specific activity of MEK1 was comparably reduced in cells growing on collagen gels (Fig. 4d). In NHBEs, the extent to which Raf was activated upon growth factor stimulation was consistently lower than the fold activation of MEK and MAPK (on either plastic dishes or collagen gels). Nevertheless, growth on collagen gels, compared to plastic dishes, also reduced the ability of growth factors to activate Raf (Fig. 4e).
Since our stimulations were performed in the presence of both exogenous EGF and insulin, we asked whether one of these signaling pathways might predominantly activate MAPK in NHBEs. Immunoblotting with an activation-specific pan-Erk1/2 antibody revealed that even at low doses (0.1 nM), EGF was a much more potent activator of MAPK than insulin (Fig. 5a, lanes 2 and 3). Since some ECMs bind growth factors tightly, collagen gels conceivably could lower the response to exogenously supplied EGF by sequestering it from the EGFR. To address this possibility, serum-free media were incubated with cells growing on collagen gels or plastic dishes; after a 15- or 45-min stimulation with growth factors, media were removed and used to stimulate NHBEs growing on plastic dishes. Immunoblotting with the activation-specific pan-Erk1/2 antibody revealed equivalent abilities of growth factors to stimulate MAPK activation regardless of whether they had been preincubated with cultures growing on plastic dishes or collagen gels (Fig. 5a, lanes 4 to 7). These data indicate that during the time course of our stimulations, exogenously supplied EGF is not sequestered by the collagen gel to the point that it is limiting. Consistent with these data, NHBEs growing on either plastic dishes or collagen gels bound similar levels of 125I-EGF (data not shown). We next examined whether growth on collagen gels impaired the ability of the EGFR to autophosphorylate. Immunoprecipitation and immunoblotting experiments following growth factor stimulation revealed comparable levels of tyrosyl-phosphorylated EGFR regardless of the substratum (Fig. 5b). These data are consistent with antiphosphotyrosine immunoblots of whole-cell lysates, which demonstrated equal amounts of a major growth factor-induced 180-kDa tyrosyl phosphoprotein (Fig. 4a).
|
Our results indicate that the reduced MAPK activation on collagen gels reflects a specific reduction in the ability of an activated EGFR to transduce a strong signal to MEK. Reduced Raf activity (Fig. 4e) is likely to account, at least partially, for the differences in MEK activation, suggesting that one point of action of ECM is upstream of Raf. Interestingly, besides the MAPKs, the only other protein that was differentially tyrosyl phosphorylated upon growth factor stimulation was 68 kDa (Fig. 4a, open arrows). We sought to identify this protein, since it might be an important component of EGFR-dependent MAPK activation in epithelial cells. In other cell systems, SHP-2 and p66SHC are the two major phosphotyrosyl proteins in this molecular weight range upon EGF stimulation (18, 36, 53), and both of these proteins are implicated in the control of MAPK activation by EGF (4, 46, 50). In NHBEs, SHP-2 was not significantly tyrosyl phosphorylated upon EGF stimulation (data not shown). In contrast, EGF induced significant tyrosyl phosphorylation of p66SHC in NHBEs (Fig. 6a). Strikingly, however, like the 68-kDa tyrosyl phosphoprotein in whole-cell lysates, p66SHC was hypophosphorylated on collagen gels upon growth factor stimulation (Fig. 6b). Notably, EGF-induced p52SHC tyrosyl phosphorylation was not impaired significantly on collagen gels (Fig. 6b); we were unable to analyze p46SHC phosphorylation in anti-SHC immunoprecipitates from NHBEs due to its close migration with the IgG heavy chain during SDS-PAGE. Both p52SHC and p66SHC can bind to the EGFR through their PTB domains, and once tyrosyl phosphorylated, they can bind to GRB2 (reviewed in reference 7). Consistent with the decrease in EGF-induced tyrosyl phosphorylation of p66SHC, growth on collagen gels diminished the ability of EGF to promote coimmunoprecipitation of p66SHC, but not p52SHC, with GRB2 (Fig. 6c). Thus, in NHBEs, extensive tyrosyl phosphorylation of both p52SHC and p66SHC, and their association with GRB2, correlates with strong MAPK activation by EGF. In contrast, tyrosyl phosphorylation of only p52SHC, and association of p52SHC alone with GRB2, correlates with weaker MAPK activation.
|
Our findings that collagen gels inhibit EGFR-dependent MAPK activation
and promote differentiation suggested that elevated MAPK activity might
inhibit mucosecretory differentiation. To test this hypothesis, we
treated randomly growing cultures of NHBEs with PD 098059, a highly
specific inhibitor of the activation of MEK by Raf (1, 16).
Strikingly, PD 098059 treatment permitted high levels of RAR
induction by retinoid in the absence of exogenous ECM (Fig.
7a). PD 098059 did not induce RAR
expression in the absence of retinoid, suggesting that it acts
on the same signaling pathway activated by growth on collagen gels
(Fig. 7b). The dose dependence for its effect on RAR
expression was
comparable to its reported dose dependence for inhibiting MAPK
activation (1, 16) (Fig. 7b). Furthermore, we confirmed that
PD 098059 inhibited MEK (Fig. 7c) and MAPK (Fig. 7d) activation by
growth factors and that this drug is extremely stable in the culture
medium, since pretreatment of cells with PD 098059 for up to 20 h
still potently inhibited MEK activation (Fig. 7e). Consistent with
our observations with PD 098059, recent preliminary experiments
indicate that infection of NHBEs with retroviruses carrying an
activated allele of MEK inhibits RAR
induction on collagen gels
(data not shown).
|
Since (i) high doses of EGF have been reported to interfere with
mucosecretory differentiation ex vivo (23, 74) and (ii) we
found that collagen gels inhibit EGF-dependent activation of MAPK, we
asked whether excessive EGFR signaling specifically contributed to the
MAPK-dependent inhibition of retinoid signaling observed in
NHBEs. We cultured NHBEs in the presence of retinoid but in the
absence of exogenous EGF. Unlike treatment with PD 098059, removal of
exogenous EGF did not promote RAR
expression in the absence of
collagen (data not shown). However, NHBEs secrete
transforming growth factor
(TGF-
) and amphiregulin, two
endogenous ligands for the EGFR (69). We therefore suspected
that an autocrine EGFR signaling loop may be predominantly responsible
for the elevated MAPK activity and inhibition of RAR
expression
observed in cells growing on plastic. Consistent with our hypothesis,
treatment of NHBEs with AG1478, a specific inhibitor of EGFR kinase
activity (37), strongly promoted RAR
expression by
retinoid in the absence of collagen (Fig.
8a). We confirmed that AG1478 was stable
in our NHBE cultures and was a potent antagonist of EGFR signaling. Pretreatment of cultures with AG1478 for up to 15 h strongly
inhibited the appearance of all major EGF-induced tyrosyl
phosphoproteins (Fig. 8b) and MAPK activation (Fig. 8c). To
independently confirm the role of the EGFR in the inhibition of
retinoid signaling in NHBEs, we cultured cells in the presence
of the anti-EGFR neutralizing antibody LA1 (31). In
agreement with our data for assays using AG1478, LA1, but not control
IgG, strongly promoted the expression of RAR
by retinoid in
the absence of collagen (Fig. 8a). Together, our data support a model
wherein collagen gels suppress an autocrine loop involving EGFR-induced
activation of MAPK and suggest that this attenuation is critical for
retinoids to induce at least some of the markers
associated with NHBE differentiation.
|
| |
DISCUSSION |
|---|
|
|
|---|
Using primary cultures of NHBEs that respond to growth factors,
retinoids, and ECM by undergoing normal differentiation
ex vivo, we have uncovered significant differences in some
established paradigms for mammalian cell signal transduction.
Retinoid-mediated induction of the prototypical
retinoid-inducible gene, RAR
, does not proceed in an
immediate-early fashion in these primary cells. Instead, its ability to
respond to retinoids requires new protein synthesis and is
regulated by an ECM/MAPK-dependent signaling pathway(s). Furthermore,
although previous work in other systems demonstrated the ability
of ECM to enhance RTK-dependent activation of MAPK
(60), we provide the first example of a cell-substratum interaction that results in inhibition of RTK-dependent MAPK
activation.
We identified RAR
as the first defined early marker for
mucosecretory differentiation of NHBEs (Fig. 2). This finding is consistent with studies of lung cancer cells, which frequently display
loss of RAR
expression (21, 49), and studies in which RAR
expression suppresses growth and tumorigenesis (20,
25) and correlates with responsiveness to chemotherapy
(42). In addition, transgenic mice expressing RAR
antisense RNA develop lung tumors (6). However, unlike in
multiple immortalized cell lines, this prototypical
retinoid-inducible gene is not an immediate-early gene in
primary NHBEs (Fig. 2b), and its transcriptional induction by
retinoids is dramatically enhanced by growth on type I collagen gels (Fig. 2a and d). Since growth on collagen gels does not appear to
regulate the transcriptional activity of either the isolated
RARE
(Fig. 3e) or a 5-kbp fragment of the RAR
5' flanking region containing the
RARE (Fig. 3f), we propose that an ECM-derived signaling pathway controls the activity of a factor distinct from the
retinoid receptors and their general coactivators.
Our finding that the MEK inhibitor PD 098059 permits high levels of
RAR
expression in cells growing on plastic (Fig. 5a) suggests that
phosphorylation by MAPK (or conceivably by MEK itself) either inhibits
the activity of retinoid receptors directly or promotes the
inhibitory activity of a factor distinct from these receptors. In cell
lines, MAPK directly phosphorylates two other nuclear hormone
receptors, the estrogen receptor (33) and peroxisome proliferator-activated receptor gamma (PPAR
) (26), and
modulates their activity on isolated hormone response elements. Since
growth on collagen gels, where there is less MEK and MAPK activation (Fig. 4c and d), does not enhance the retinoid inducibility of a minimal
RARE-containing promoter (Fig. 3e) or the 5-kbp fragment of the RAR
promoter (Fig. 3f), we favor a model in which MAPK does
not directly affect retinoid receptors but instead promotes the
inhibitory properties of a novel factor that likely requires cis-acting sequences outside the 5-kbp promoter region for
its inhibitory activity. Notably, and consistent with our proposal, MAPK does not affect RAR
phosphorylation in COS cells
(56), and a 3.8-kbp fragment of the murine RAR
5'
flanking region cannot confer bronchial cell-specific expression in
transgenic mice (45).
The ability of ECM to promote MAPK activation by acute engagement of integrins has been studied extensively in assays using cell lines. Immediately upon integrin engagement or attachment to ECM, PTKs are activated, leading to MAPK activation (reviewed in reference 10). Consistent with the above studies, tyrosine kinase signaling was acutely activated during the initial stages of NHBE attachment to collagen gels (data not shown). However, NHBEs, like other epithelial cells, do not continuously detach and reattach to their underlying substratum in vivo. Therefore, a more physiologically relevant question is how long-term growth on an ECM that supports differentiation modulates the ability of cells to activate MAPKs in response to growth factors. Indeed, under such conditions (long-term growth on collagen gels), NHBEs exhibit a decreased ability to activate MEK and MAPK in response to EGF (Fig. 4c, 4d, and 5a). This inhibition cannot be attributed to limiting amounts of EGF in the culture medium (Fig. 5a) or a general inability of EGF to promote high levels of EGFR autophosphorylation (Fig. 5b). However, the inhibition of MEK activation does correlate with a reduced ability to activate Raf (Fig. 4e) and the inability of EGF to promote extensive tyrosyl phosphorylation of a major 68-kDa protein (Fig. 4a), which we have identified as p66SHC (Fig. 6b).
SHC proteins have been implicated in Ras activation by a number of growth factors (for a review, see reference 7), but little is known about the role of specific SHC proteins during normal, physiologic responses. The recently cloned p66SHC (46, 50) differs from p52SHC by virtue of an additional collagen homology domain (CH2) in its amino terminus. Like p52SHC, p66SHC binds to the EGFR and GRB2 (46, 50). In CHO/IR/ER cells, overexpression of p66SHC inhibits EGF-dependent MAPK activation (50), while in COS and HeLa cells, overexpression of p66SHC has no effect on EGF-dependent MAPK activation but does inhibit EGF-dependent c-fos promoter activation (46). In contrast, in HC-11 mouse mammary epithelial cells, cripto-1-dependent association of SOS with SHC proteins and activation of MAPK is correlated more strongly with p66SHC tyrosyl phosphorylation than with p52SHC tyrosyl phosphorylation (32). We observe that in NHBEs growing on plastic, where EGF promotes extensive tyrosyl phosphorylation of both p52SHC and p66SHC and association of both SHC proteins with GRB2, MEK and MAPK activation is strong (Fig. 4 and 6). In contrast, on collagen gels, where EGF selectively fails to promote extensive tyrosyl phosphorylation of p66SHC and its association with GRB2, there is less Raf, MEK and MAPK activation (Fig. 4 and 6). In NHBEs, the total level of Ras activation integrated over time may depend on the recruitment of both pools of SHC to the EGFR. By virtue of its unique CH2 domain, the tyrosyl phosphorylation status of p66SHC, and hence its ability to regulate EGFR signaling, may be sensitive to novel signaling pathways activated in epithelial cells by growth on differentiation-promoting ECMs. One attractive possibility is that the 120- and/or 130-kDa tyrosyl phosphoproteins that exhibit different levels of basal phosphorylation on plastic and collagen gels (Fig. 4a) may be part of a signaling pathway that regulates p66SHC phosphorylation. Preliminary experiments indicate that the 120-kDa protein is not FAK and the 130-kDa protein is not p130CAS (data not shown). Due to reagent limitations, we have not yet been able to determine whether the 130-kDa protein that is hyperphosphorylated on collagen gels is either of the newly identified collagen receptors DDR1 and DDR2 (64, 71).
Since (i) collagen gels inhibit EGFR-dependent activation of MEK and
MAPK and promote the induction of RAR
by retinoids, (ii)
direct inhibition of EGFR signaling by AG1478 or anti-EGFR neutralizing
antibodies promotes RAR
induction by retinoids, and (iii)
specific inhibition of Raf-dependent MEK/MAPK activation by treatment
with PD 098059 also promotes retinoid inducibility of the
RAR
gene, we propose that collagen gels promote the retinoid responsiveness of the RAR
gene by reducing the level of
EGFR-dependent MEK/MAPK activity (Fig. 9). Thus, in vivo, the role of
ECM in modulating MAPK activation in response to growth factors is
likely to be cell type dependent. For example, fibroblasts, which
normally respond to growth factors at sites of wounding by undergoing
proliferation, display enhanced MAPK activation and growth in response
to PDGF when cultured on ECMs such as vitronectin (60). In
contrast, NHBEs are designed to undergo differentiation when growing on their normal ECM, and accordingly display reduced activation of MAPK by
growth factors, when cultured on differentiation-promoting collagen
gels.
Although treatment with PD 098059, AG1478, or LA1 promoted
retinoid-dependent induction of RAR
, none of these agents
could promote the induction of mucous glycoprotein expression in
the absence of collagen gels (data not shown). This most likely
reflects the involvement of MAPK-dependent and independent pathways in regulating mucosecretory differentiation. Given that NHBEs secrete TGF-
and amphiregulin, we propose that ECM restricts the extent of
EGFR-dependent MEK/MAPK activation that occurs in the bronchial epithelium in response to both autocrine (TGF-
and amphiregulin) and paracrine (EGF) growth factors (Fig.
9). This would be critical for minimizing
the inhibitory effects of MAPK on retinoid-dependent transcription of target genes such as RAR
, which are likely to be
involved in differentiation.
|
The antidifferentiative role of MAPKs in NHBE mucosecretory differentiation contrasts with their role in PC12 cell neuronal differentiation (12, 67) but is similar to their role in 3T3-L1 adipocyte (19) and myoblast differentiation (5, 11). Strikingly, specific restriction of the amount of EGFR-dependent MAPK activation is critical for retinoids to induce at least some of the target genes normally induced during NHBE differentiation. This would suggest that part of the mechanism of carcinogenesis in the lung, in which overexpression of the EGFR and/or other EGFR family members is frequent (reviewed in reference 58), may involve antagonism of the differentiation-promoting activity of retinoids. This may also explain the limited success of retinoid therapy in treating lung cancer (41). Accordingly, combination therapy of EGFR antagonists and retinoids might be more effective. Further study of primary cell systems such as NHBEs should continue to provide important insight into epithelial cell signaling pathways and their perturbation in disease states like cancer.
| |
ACKNOWLEDGMENTS |
|---|
We thank M. Klaus for Ro 19-0645, R. Wu for antimucin antibody
17B1, W. Pear for BING cells, W. Chin for
RXR antibodies, R. L. Erikson, B. Brott, A. Alessandrini, and Y. Gotoh for
MEK antibodies
and GST-Erk1(K63M) fusion protein, K. L. Guan for
GST-MEK(K97A) fusion protein, J. Blenis for
Erk1/2
antiserum, S. Soltoff for AG1478, and J. Timms for assistance with the
final stages of this work. We also thank Y. Gotoh, L. Klaman, C. Carpenter, and K. Carraway for helpful discussions.
This work was supported by grant CA-49152 from the National Institutes of Health to B.G.N.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Cancer Biology Program and Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. Phone: (617) 667-2823. Fax: (617) 667-0610. E-mail: bneel{at}bidmc.harvard.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alessi, D. R.,
A. Cuenda,
P. Cohen,
D. T. Dudley, and A. R. Saltiel.
1995.
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
J. Biol. Chem.
270:27489-27494 |
| 2. |
Apfel, C.,
F. Bauer,
M. Crettaz,
L. Forni,
M. Kamber,
F. Kaufmann,
P. LeMotte,
W. Pirson, and M. Klaus.
1992.
A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects.
Proc. Natl. Acad. Sci. USA
89:7129-7133 |
| 3. | Ausubel, F., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1987. Current protocols in molecular biology, vol. 1. Greene Publishing Associates, New York, N.Y. |
| 4. | Bennett, A. M., S. E. Hausdorff, A. M. O'Reilly, R. M. Freeman, and B. G. Neel. 1996. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell. Biol. 16:1189-1202[Abstract]. |
| 5. |
Bennett, A. M., and N. K. Tonks.
1997.
Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases.
Science
278:1288-1291 |
| 6. |
Berard, J.,
F. Laboune,
M. Mukuna,
S. Masse,
R. Kothary, and W. E. C. Bradley.
1996.
Lung tumors in mice expressing an antisense RAR 2 transgene.
FASEB J.
10:1091-1097[Abstract].
|
| 7. | Bonfini, L., E. Migliaccio, G. Pelicci, L. Lanfrancone, and P. G. Pelicci. 1996. Not all Shc's roads lead to Ras. Trends Biochem. Sci. 21:257-261[Medline]. |
| 8. | Chambon, P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J. 10:940-954[Abstract]. |
| 9. |
Chen, Q.,
M. S. Kinch,
T. H. Lin,
K. Burridge, and R. L. Juliano.
1994.
Integrin-mediated cell adhesion activates mitogen-activated protein kinases.
J. Biol. Chem.
269:26602-26605 |
| 10. |
Clark, E. A., and J. S. Brugge.
1995.
Integrins and signal transduction pathways: the road taken.
Science
268:233-239 |
| 11. |
Coolican, S. A.,
D. S. Samuel,
D. Z. Ewton,
F. J. McWade, and J. R. Florini.
1997.
The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways.
J. Biol. Chem.
272:6653-6662 |
| 12. | Cowley, S., H. Paterson, P. Kemp, and C. J. Marshall. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77:841-852[Medline]. |
| 13. |
de The, H.,
A. Marchio,
P. Tiollais, and A. Dejean.
1989.
Differential expression and ligand regulation of the retinoic acid receptor and genes.
EMBO J.
8:429-433[Medline].
|
| 14. |
de The, H.,
M. D. M. Vivanco-Ruiz,
P. Tiollais,
H. Stunnenberg, and A. Dejean.
1990.
Identification of a retinoic acid responsive element in the retinoic acid receptor gene.
Nature (London)
343:177-180[Medline].
|
| 15. |
Dolle, P.,
E. Ruberte,
P. Leroy,
G. Morriss-Kay, and P. Chambon.
1990.
Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis.
Development
110:1133-1151 |
| 16. |
Dudley, D. T.,
L. Pang,
S. J. Decker,
A. J. Bridges, and A. R. Saltiel.
1995.
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Proc. Natl. Acad. Sci. USA
92:7686-7689 |
| 17. | Edwards, G., and C. Streuli. 1995. Signaling in extracellular matrix-mediated control of epithelial cell phenotype. Biochem. Soc. Trans. 23:464-468[Medline]. |
| 18. |
Feng, G. S.,
C. C. Hui, and T. Pawson.
1993.
SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases.
Science
259:1607-1611 |
| 19. | Font de Mora, J., A. Porras, N. Ahn, and E. Santos. 1997. Mitogen-activated protein kinase activation is not necessary for, but antagonizes, 3T3-L1 adipocyte differentiation. Mol. Cell. Biol. 17:6068-6075[Abstract]. |
| 20. |
Frangioni, J. V.,
N. Moghal,
A. Stuart-Tilley,
B. G. Neel, and S. L. Alper.
1994.
The DNA binding domain of retinoic acid receptor is required for ligand-dependent suppression of proliferation.
J. Cell Sci.
107:827-838[Abstract].
|
| 21. |
Gebert, J. F.,
N. Moghal,
J. V. Frangioni,
D. J. Sugarbaker, and B. G. Neel.
1991.
High frequency of retinoic acid receptor abnormalities in human lung cancer.
Oncogene
6:1859-1868[Medline].
|
| 22. |
Geisen, C.,
C. Denk,
B. Gremm,
C. Baust,
A. Karger,
W. Bollag, and E. Schwarz.
1997.
High-level expression of the retinoic acid receptor beta gene in normal cells of the uterine cervix is regulated by the retinoic acid receptor alpha and is abnormally down-regulated in cervical carcinoma cells.
Cancer Res.
57:1460-1467 |
| 23. | Gray, T. E., K. Guzman, C. W. Davis, L. H. Abdullah, and P. Nettesheim. 1996. Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 14:104-112[Abstract]. |
| 24. | Harkema, J., A. Mariassy, J. St. George, D. M. Hyde, and C. G. Plopper. 1991. Epithelial cells of the conducting airways, p. 3-39. In S. G. Farmer, and D. W. P. Hay (ed.), The airway epithelium. Marcel Dekker, Inc., New York, N.Y. |
| 25. |
Houle, B.,
C. Rochette-Egly, and W. E. C. Bradley.
1993.
Tumor-suppressive effect of the retinoic acid receptor in human epidermoid lung cancer cells.
Proc. Natl. Acad. Sci. USA
90:985-989 |
| 26. |
Hu, E.,
J. B. Kim,
P. Sarraf, and B. M. Spiegelman.
1996.
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR .
Science
274:2100-2103 |
| 27. |
Hu, L.,
D. L. Crowe,
J. G. Rheinwald,
P. Chambon, and L. Gudas.
1991.
Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines.
Cancer Res.
51:3972-3981 |
| 28. | Jetten, A. M. 1989. Multistep process of squamous differentiation in tracheobronchial epithelial cells in vitro: analogy with epidermal differentiation. Environ. Health Perspect. 80:149-160[Medline]. |
| 29. | Jetten, A. M., A. R. Brody, M. A. Deas, G. E. R. Hook, J. I. Rearick, and S. M. Thacher. 1987. Retinoic acid and substratum regulate the differentiation of rabbit tracheal epithelial cells into squamous and secretory phenotype. Lab. Investig. 56:654-664[Medline]. |
| 30. |
Jetten, A. M., and J. E. Shirley.
1986.
Characterization of transglutaminase activity in rabbit tracheal epithelial cells.
J. Biol. Chem.
261:15097-15101 |
| 31. |
Johnson, G. R.,
B. Kannan,
M. Shoyab, and K. Stromberg.
1993.
Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells.
J. Biol. Chem.
268:2924-2931 |
| 32. |
Kannan, S.,
M. De Santis,
M. Lohmeyer,
D. J. I. Riese,
G. H. Smith,
N. Hynes,
M. Seno,
R. Brandt,
C. Bianco,
G. Perisco,
N. Kenney,
N. Normanno,
I. Martinez-Lacaci,
F. Ciardiello,
D. F. Stern,
W. J. Gullick, and D. J. Salomon.
1997.
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells.
J. Biol. Chem.
272:3330-3335 |
| 33. |
Kato, S.,
H. Endoh,
Y. Masuhiro,
T. Kitamoto,
S. Uchiyama,
H. Sasaki,
S. Masushige,
Y. Gotoh,
E. Nishida,
H. Kawashima,
D. Metger, and P. Chambon.
1995.
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.
Science
270:1491-1494 |
| 34. | Kazlauskas, A. 1994. Receptor tyrosine kinases and their targets. Curr. Opin. Genet. Dev. 4:5-14[Medline]. |
| 35. | King, W. G., M. D. Mattaliano, T. O. Chan, P. N. Tsichlis, and J. S. Brugge. 1997. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol. Cell. Biol. 17:4406-4418[Abstract]. |
| 36. | Lechleider, R. J., R. M. Freeman, and B. G. N |